- Home
- NML vs EYPT Comparison
NML vs EYPT Comparison
Compare NML & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NML
- EYPT
- Stock Information
- Founded
- NML 2012
- EYPT 1987
- Country
- NML United States
- EYPT United States
- Employees
- NML N/A
- EYPT N/A
- Industry
- NML Finance/Investors Services
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- NML Finance
- EYPT Industrials
- Exchange
- NML Nasdaq
- EYPT Nasdaq
- Market Cap
- NML 454.4M
- EYPT 390.0M
- IPO Year
- NML N/A
- EYPT 2005
- Fundamental
- Price
- NML $8.52
- EYPT $5.81
- Analyst Decision
- NML
- EYPT Strong Buy
- Analyst Count
- NML 0
- EYPT 7
- Target Price
- NML N/A
- EYPT $24.00
- AVG Volume (30 Days)
- NML 219.3K
- EYPT 647.7K
- Earning Date
- NML 01-01-0001
- EYPT 05-07-2025
- Dividend Yield
- NML 9.75%
- EYPT N/A
- EPS Growth
- NML N/A
- EYPT N/A
- EPS
- NML N/A
- EYPT N/A
- Revenue
- NML N/A
- EYPT $56,042,000.00
- Revenue This Year
- NML N/A
- EYPT N/A
- Revenue Next Year
- NML N/A
- EYPT N/A
- P/E Ratio
- NML N/A
- EYPT N/A
- Revenue Growth
- NML N/A
- EYPT 12.04
- 52 Week Low
- NML $6.09
- EYPT $3.91
- 52 Week High
- NML $7.33
- EYPT $21.26
- Technical
- Relative Strength Index (RSI)
- NML 49.54
- EYPT 44.22
- Support Level
- NML $8.20
- EYPT $5.75
- Resistance Level
- NML $8.54
- EYPT $7.45
- Average True Range (ATR)
- NML 0.20
- EYPT 0.50
- MACD
- NML 0.03
- EYPT -0.07
- Stochastic Oscillator
- NML 58.33
- EYPT 3.53
About NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States. Invest in Capital Markets, Chemicals, Oil, Gas & Consumable Fuels, Electric Utilities, Independent Power and Renewable Electricity Producers, Multi Utilities. Maximum is done in Oil, Gas & Consumable Fuels.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.